NCT00065676

Brief Summary

Quercetin is a compound naturally found in various foods. It may have some role in the treatment of obesity and diabetes. The purpose of this study is to investigate research volunteers with obesity or obesity with type 2 diabetes to determine whether quercetin affects the way glucose is absorbed by the body. Thirty two participants aged 19 to 65 who are considered to be medically obese or obese with type 2 diabetes will be enrolled in this study. Before the onset of treatment, they will undergo a medical history, physical exam, blood work, and urinalysis. During the study, participants will be given an oral glucose tolerance test three times; during these tests they will receive 1 or 2 grams of quercetin, or placebo. Researchers will collect blood samples and analyze the effect of the treatment on blood glucose. ...

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for phase_2 obesity

Timeline
Completed

Started Apr 2010

Longer than P75 for phase_2 obesity

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 30, 2003

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 31, 2003

Completed
6.8 years until next milestone

Study Start

First participant enrolled

April 30, 2010

Completed
5.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 21, 2015

Completed
5.6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 6, 2021

Completed
Last Updated

April 8, 2026

Status Verified

January 22, 2026

Enrollment Period

5.6 years

First QC Date

July 30, 2003

Last Update Submit

April 7, 2026

Conditions

Keywords

HyperglycemiaHyperinsulinemiaOGTTGLUT2Post-PrandialType 2 DiabetesObesity

Outcome Measures

Primary Outcomes (1)

  • Does quercetin effect glucose absorption

    Reduction in plasma glucose concentrations during 6-hour oral glucose tolerance test with 1 gram quercetin vs 2 grams quercetin vs placebo.

    End of study

Study Arms (3)

1 gram quercetin

EXPERIMENTAL

1 gram quercetin with 6 hour OGTT

Other: Quercetin

2 grams quercetin

EXPERIMENTAL

2 gram quercetin with 6 hour OGTT

Other: Quercetin

placebo

EXPERIMENTAL

placebo with 6 hour OGTT

Other: Placebo

Interventions

PlaceboOTHER
placebo

1 or 2 grams of quercetin or placebo will be given while patients undergo 6-hour OGTT

1 gram quercetin2 grams quercetin

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

  • Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycaemia. Drugs. 1999 Jan;57(1):19-29. doi: 10.2165/00003495-199957010-00003.

    PMID: 9951949BACKGROUND
  • Gavin JR 3rd. Pathophysiologic mechanisms of postprandial hyperglycemia. Am J Cardiol. 2001 Sep 20;88(6A):4H-8H. doi: 10.1016/s0002-9149(01)01830-6.

    PMID: 11576519BACKGROUND
  • Yanovski SZ, Yanovski JA. Obesity. N Engl J Med. 2002 Feb 21;346(8):591-602. doi: 10.1056/NEJMra012586. No abstract available.

    PMID: 11856799BACKGROUND

Related Links

MeSH Terms

Conditions

ObesityDiabetes MellitusHyperglycemiaHyperinsulinismDiabetes Mellitus, Type 2

Interventions

Quercetin

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsGlucose Metabolism DisordersMetabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

FlavonolsFlavonoidsChromonesBenzopyransPyransHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Officials

  • Mark A Levine, M.D.

    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
NIH
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 30, 2003

First Posted

July 31, 2003

Study Start

April 30, 2010

Primary Completion

December 21, 2015

Study Completion

August 6, 2021

Last Updated

April 8, 2026

Record last verified: 2026-01-22

Locations